WUXI APPTEC - Overseas Regulatory Announcement - Other

does not make any representation about the accuracy or completeness of this announcement and expressly disclaims any liability arising out of or in connection with all or any part of this announcement. We are not responsible for any losses caused by reliance on such content.

WUXI APPTEC CO., LTD.* Wuxi WuXi AppTec New Drug Development Co., Ltd.

(a joint stock limited company incorporated in the People's Republic of China) (Stock code: 2359)

Overseas Regulatory Announcements

This overseas regulatory announcement is made by the Company in accordance with Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited

Section 13.10B is made.

The full Chinese text of the following information published by the Company on the Shanghai Stock Exchange website is hereby provided for reference only.

By order of the board of directors Wuxi WuXi AppTec New Drug Development Co., Ltd. Chairman

Dr. Li Ge

Hong Kong, August 3, 2026

As of the date of this announcement, the Company's Board of Directors includes executive directors Dr. Li Ge, Dr. Chen Minzhang, Dr. Yang Qing and Mr. Zhang Zhaohui; Non-executive directors Mr. Tong Xiaoyi and Dr. Wu Yibing; and independent non-executive directors Ms. Lu Shaohua, Dr. Yu Wei, Dr. Zhang Xin, Ms. Zhan Zhiling and Mr. Leng Xuesong.

*For identification only

Remuneration and Assessment Committee of the Board of Directors of Wuxi WuXi AppTec New Drug Development Co., Ltd.

Verification opinions on matters related to the company’s 2026 A-share employee stock ownership plan

Remuneration and evaluation of the board of directors of Wuxi WuXi AppTec New Drug Development Co., Ltd. (hereinafter referred to as the "Company")

The Nuclear Committee shall, in accordance with the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China and the Regulations on Listed Companies. Guiding Opinions on the Implementation of Pilot Employee Stock Ownership Plans by Companies" (hereinafter referred to as "Guiding Opinions"), "Shanghai Securities

Self-regulatory Guidelines for Listed Companies on the Stock Exchange No. 1 - Standardized Operations (hereinafter referred to as "Self-regulatory Supervision")

"Guidelines") as well as other laws, administrative regulations, rules, normative documents and "Wuxi WuXi AppTec New Drugs

According to the relevant provisions of the Articles of Association of Development Co., Ltd., the company’s 2026 A-share employee stock ownership plan (hereinafter

The verification opinions on relevant matters (referred to as "this Employee Stock Ownership Plan") are as follows:

1. The company does not have any laws, administrative regulations, rules or regulations such as the "Guiding Opinions" or "Self-Regulation Guidelines".

The implementation of employee stock ownership plans is prohibited as specified in normative documents.

2. The participants in the company's employee stock ownership plan are all in compliance with the "Guiding Opinions" and "Self-Discipline Supervision Guidelines".

"Introduction" and other laws, administrative regulations, rules, normative documents stipulated in the conditions for participation, in line with employee stock ownership

The scope of participants specified in the plan is subject to qualifications as a participant in the company's employee stock ownership plan.

Legal and effective.

3. The company’s source of funds for this employee stock ownership plan is the long-term incentive fund drawn by the company, that is, the company

The special incentive fund accrued in accordance with salary-related management regulations is part of the employees' total remuneration. This time

There is no third party in the Employee Stock Ownership Plan that provides rewards, subsidies, or protection for employees participating in this Employee Stock Ownership Plan. Waiting for arrangements.

4. The company’s “2026 A-share Employee Stock Ownership Plan (Draft)” and “2026 A-share Employee Stock Ownership Plan”

The content of the Management Measures complies with laws, administrative regulations, rules, etc. According to the provisions of normative documents, this employee stock ownership plan will not harm the interests of the company and all shareholders.

5. The company formulates and reviews the company’s “2026 A-Share Employee Stock Ownership Plan (Draft)” and “2026 A-Share Employee Stock Ownership Plan (Draft)”

The procedures of the Measures for the Administration of Employee Stock Ownership Plans are legal and effective.

6. The company’s implementation of this employee stock ownership plan is conducive to the company’s sustainable development. This employee stock ownership plan includes

It helps to further improve the company's corporate governance structure, establish and improve the company's long-term incentive and restraint mechanism, and attract and

Retain outstanding talents, fully mobilize their enthusiasm and creativity, and effectively enhance the cohesion of core employees and the core value of the enterprise

Focus on core competitiveness and combine the interests of shareholders, the company and core employees so that all parties can focus on the company long-term development and ensure the realization of the company's future long-term sustainable development strategy and business objectives.

7. The company does not force employees to participate in this employee stock ownership plan through apportionment, forced distribution, etc.

situation.

In summary, the Remuneration and Appraisal Committee of the Company’s Board of Directors agreed to implement this employee stock ownership plan and agreed to

Matters related to the employee stock ownership plan were submitted to the company's board of directors for review.

Wuxi WuXi AppTec New Drug Development Co., Ltd.

Remuneration and Appraisal Committee of the Board of Directors

August 3, 2026